understanding cholesterol effects of adalimumab by new techniques was another goal of gelfand and mehta's study..
..
.
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people..
novartis india appoints milan paleja as vice chairman and md